{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:07:51Z","timestamp":1789538871965,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Bristol Myers Squibb"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-025-05589-2","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T13:49:08Z","timestamp":1743688148000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-effectiveness of nivolumab compared with surveillance for adjuvant treatment of muscle-invasive urothelial carcinoma at high risk of recurrence in France"],"prefix":"10.1007","volume":"43","author":[{"given":"Sylvie","family":"Negrier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Bonastre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Colrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siguroli","family":"Teitsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Chevalier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Branchoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"5589_CR1","doi-asserted-by":"publisher","unstructured":"Huang AC, Zappasodi R (2022) A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance. Nat Immunol 23(5):660\u2013\u200970. https:\/\/doi.org\/10.1038\/s41590-022-01141-1","DOI":"10.1038\/s41590-022-01141-1"},{"issue":"5","key":"5589_CR2","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, Ladwa R, O\u2019Byrne K, Kulasinghe A (2022) Immune checkpoint inhibitors in cancer therapy. Curr Oncol 29(5):3044\u20133060. https:\/\/doi.org\/10.3390\/curroncol29050247","journal-title":"Curr Oncol"},{"key":"5589_CR3","doi-asserted-by":"publisher","unstructured":"Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat SF, Park SH, Ye D, Agerbaek M, Enting D, McDermott R, Gajate P, Peer A, Milowsky MI, Nosov A, Neif Antonio J Jr., Tupikowski K, Toms L, Fischer BS, Qureshi A, Collette S, Unsal-Kacmaz K, Broughton E, Zardavas D, Koon HB, Galsky MD (2021) Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med 384(22):2102-14. https:\/\/doi.org\/10.1056\/NEJMoa2034442","DOI":"10.1056\/NEJMoa2034442"},{"key":"5589_CR4","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Methodological guidance. Choices in methods for economic evaluation. St Denis: HAS (2020) Available from: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2020-11\/methodological_guidance_2020_-choices_in_methods_for_economic_evaluation.pdf"},{"key":"5589_CR5","doi-asserted-by":"publisher","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S, Force CIGRPT (2022) Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Value Health 25(1):3\u20139. https:\/\/doi.org\/10.1016\/j.jval.2021.11.1351","DOI":"10.1016\/j.jval.2021.11.1351"},{"key":"5589_CR6","doi-asserted-by":"publisher","unstructured":"Latimer NR (2013) Survival analysis for economic evaluations alongside clinical trials\u2013extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Mak 33(6):743\u2013754. https:\/\/doi.org\/10.1177\/0272989X12472398","DOI":"10.1177\/0272989X12472398"},{"key":"5589_CR7","doi-asserted-by":"publisher","first-page":"S1342","DOI":"10.1016\/j.annonc.2022.07.1836","volume":"33","author":"A Fraslin","year":"2022","unstructured":"Fraslin A, Colrat FP, Karimi M, Bonastre J, Karine G, Teitsson S, Prudent A, Branchoux S, Radvanyi F, Benhamou S, Allory Y, Lebret T (2022) Characteristics, management and survival outcomes of French patients (pts) with muscle invasive bladder cancer (MIBC) at high risk of recurrence (MIBC-HR): A study based on the coblance cohort. Ann Oncol 33:S1342. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.1836","journal-title":"Ann Oncol"},{"issue":"12","key":"5589_CR8","doi-asserted-by":"publisher","first-page":"e075942","DOI":"10.1136\/bmjopen-2023-075942","volume":"13","author":"T Lebret","year":"2023","unstructured":"Lebret T, Bonastre J, Fraslin A, Neuzillet Y, Droupy S, Rebillard X, Vordos D, Guy L, Villers A, Schneider M, Coloby P, Lacoste J, Mejean A, Lacoste J, Descotes JL, Eschwege P, Loison G, Blanche H, Mariani O, Ghaleh B, Mangin A, Sirab N, Groussard K, Radvanyi F, Allory Y, Benhamou S (2023) Cohort profile: coblance: a French prospective cohort to study prognostic and predictive factors in bladder cancer and to generate real-world data on treatment patterns, resource use and quality of life. BMJ Open 13(12):e075942. https:\/\/doi.org\/10.1136\/bmjopen-2023-075942","journal-title":"BMJ Open"},{"key":"5589_CR9","doi-asserted-by":"publisher","unstructured":"Witjes JA, Bruins HM, Cathomas R, Comperat EM, Cowan NC, Gakis G, Hernandez V, Linares Espinos E, Lorch A, Neuzillet Y, Rouanne M, Thalmann GN, Veskimae E, Ribal MJ, van der Heijden AG (2021) European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol 79(1):82\u2013104. https:\/\/doi.org\/10.1016\/j.eururo.2020.03.055","DOI":"10.1016\/j.eururo.2020.03.055"},{"issue":"Suppl 1","key":"5589_CR10","doi-asserted-by":"publisher","first-page":"R34","DOI":"10.1016\/j.purol.2019.01.005","volume":"28","author":"M Roupret","year":"2018","unstructured":"Roupret M, Xylinas E, Colin P, Houede N, Comperat E, Audenet F, Larre S, Masson-Lecomte A, Pignot G, Brunelle S, Roumiguie M, Neuzillet Y, Mejean A (2018) [French CcAFU guidelines - Update 2018\u20132020: upper tract urothelial carcinoma]. Prog Urol 28(Suppl 1):R34\u2013R47. https:\/\/doi.org\/10.1016\/j.purol.2019.01.005","journal-title":"Prog Urol"},{"key":"5589_CR11","doi-asserted-by":"publisher","unstructured":"Bellmunt J, von der Maase H, Mead GM, Skoneczna I, De Santis M, Daugaard G, Boehle A, Chevreau C, Paz-Ares L, Laufman LR, Winquist E, Raghavan D, Marreaud S, Collette S, Sylvester R, de Wit R (2012) Randomized phase III study comparing paclitaxel\/cisplatin\/gemcitabine and gemcitabine\/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol 30(10):1107-13. https:\/\/doi.org\/10.1200\/JCO.2011.38.6979","DOI":"10.1200\/JCO.2011.38.6979"},{"issue":"2","key":"5589_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","volume":"30","author":"M De Santis","year":"2012","unstructured":"De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, Gil T, Marreaud S, Daugaard G, Skoneczna I, Collette S, Lorent J, de Wit R, Sylvester R (2012) Randomized phase II\/III trial assessing Gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 30(2):191\u2013199. https:\/\/doi.org\/10.1200\/JCO.2011.37.3571","journal-title":"J Clin Oncol"},{"key":"5589_CR13","doi-asserted-by":"publisher","first-page":"LBA443","DOI":"10.1200\/JCO.2023.41.6_suppl.LBA443","volume":"41","author":"M Galsky","year":"2023","unstructured":"Galsky M, Witjes A, Gschwend J, Schenker M, P\u00e9rez Valderrama B, Tomita Y, Bamias A, Lebret T, Shariat F, Park S, Agerbaek M, Gopalji Jha G, Stenner F, Dutta S, Nasroulah F, Zhang J, Brophy L, Bajorin D (2023) Extended follow-up results from the checkmate 274 trial. J Clin Oncol 41:LBA443","journal-title":"J Clin Oncol"},{"key":"5589_CR14","unstructured":"INSEE. Tables de mortalit\u00e9 par sexe, \u00e2ge et niveau de vie\u2013\u2009Tables de mortalit\u00e9 par niveau de vie (2021) Available from: https:\/\/www.insee.fr\/fr\/statistiques\/3311422?sommaire=3311425."},{"issue":"6","key":"5589_CR15","first-page":"1197","volume":"22","author":"C Bakker","year":"1995","unstructured":"Bakker C, van der Linden S (1995) Health related utility measurement: an introduction. J Rheumatol 22(6):1197\u20131199","journal-title":"J Rheumatol"},{"key":"5589_CR16","doi-asserted-by":"publisher","unstructured":"Rabin R, de Charro F (2001) EQ-5D: a measure of health status from the EuroQol Group. Ann Med 33(5):337\u2013\u200943. https:\/\/doi.org\/10.3109\/07853890109002087","DOI":"10.3109\/07853890109002087"},{"key":"5589_CR17","doi-asserted-by":"publisher","unstructured":"Witjes JA, Galsky MD, Gschwend JE, Broughton E, Braverman J, Nasroulah F, Maira-Arce M, Ye X, Shi L, Guo S, Hamilton M, Bajorin DF (2022) Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial. Eur Urol Oncol 5(5):553\u2013\u200963. https:\/\/doi.org\/10.1016\/j.euo.2022.02.003","DOI":"10.1016\/j.euo.2022.02.003"},{"key":"5589_CR18","doi-asserted-by":"publisher","unstructured":"Chevalier J, de Pouvourville G (2013) Valuing EQ-5D using time trade-off in France. Eur J Health Econ 14(1):57\u201366. https:\/\/doi.org\/10.1007\/s10198-011-0351-x","DOI":"10.1007\/s10198-011-0351-x"},{"key":"5589_CR19","unstructured":"Agence Technique de l\u2019Information sur l\u2019Hospitalisation. Lyon: ATIH (2021) Available from: https:\/\/www.scansante.fr\/applications\/donnees-de-couts"},{"key":"5589_CR20","unstructured":"INSEE. Indice des prix \u00e0 la consommation - Base 2015 - Ensemble des m\u00e9nages - France m\u00e9tropolitaine - Nomenclature Coicop: 06 - Sant\u00e9 (2023) Available from: https:\/\/www.inseefr\/fr\/statistiques\/serie\/001764069"},{"key":"5589_CR21","unstructured":"INSEE. Indice des prix \u00e0 la consommation - Base 2015 - Ensemble des m\u00e9nages - France m\u00e9tropolitaine - Nomenclature Coicop: 06.2.1.2 - M\u00e9decins sp\u00e9cialistes 2023. Available from: https:\/\/www.insee.fr\/fr\/statistiques\/serie\/001764083#"},{"key":"5589_CR22","unstructured":"INSEE. Indice des prix \u00e0 la consommation - Base 2015 - Ensemble des m\u00e9nages - France m\u00e9tropolitaine - Nomenclature Coicop: 06.2.1.1 - M\u00e9decins g\u00e9n\u00e9ralistes 2023. Available from: https:\/\/www.insee.fr\/fr\/statistiques\/serie\/001764082#"},{"key":"5589_CR23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation","author":"AHC Briggs","year":"2006","unstructured":"Briggs AHC, Sculpher K (2006) M.J. Decision modelling for health economic evaluation. Oxford University Press, Oxford, p 237"},{"issue":"8","key":"5589_CR24","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.jval.2020.04.001","volume":"23","author":"B T\u00e9hard","year":"2020","unstructured":"T\u00e9hard B, Detournay B, Borget I, Roze S, De Pouvourville G (2020) Value of a QALY for France: A new approach to propose acceptable reference values. Value Health 23(8):985\u2013993. https:\/\/doi.org\/10.1016\/j.jval.2020.04.001","journal-title":"Value Health"},{"key":"5589_CR25","doi-asserted-by":"publisher","unstructured":"Galsky MD, Witjes JA, Gschwend JE, Milowsky MI, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat SF, Park SH, Agerbaek M, Jha G, Stenner F, Ye D, Giudici F, Dutta S, Askelson M, Nasroulah F, Zhang J, Brophy L, Bajorin DF (2025) Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274. J Clin Oncol 43(1):15\u201321. https:\/\/doi.org\/10.1200\/jco.24.00340","DOI":"10.1200\/jco.24.00340"},{"issue":"5","key":"5589_CR26","doi-asserted-by":"publisher","first-page":"e0302548","DOI":"10.1371\/journal.pone.0302548","volume":"19","author":"F Porte","year":"2024","unstructured":"Porte F, Granghaud A, Chang J, Kearney M, Morel A, Plessala I, Cawston H, Roiz J, Xiao Y, Solbes MN, Lambert P, Ravaud A, Loriot Y, Thiery-Vuillemin A, L\u00e9vy P (2024) Cost-effectiveness of avelumab first-line maintenance therapy for adult patients with locally advanced or metastatic urothelial carcinoma in France. PLoS ONE 19(5):e0302548. https:\/\/doi.org\/10.1371\/journal.pone.0302548","journal-title":"PLoS ONE"},{"key":"5589_CR27","doi-asserted-by":"publisher","unstructured":"Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Dur\u00e1n I, Lee JL, Matsubara N, Vulsteke C, Castellano D, Wu C, Campbell M, Matsangou M, Petrylak DP (2021) Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med 384(12):1125-35. https:\/\/doi.org\/10.1056\/NEJMoa2035807","DOI":"10.1056\/NEJMoa2035807"},{"key":"5589_CR28","doi-asserted-by":"publisher","unstructured":"Brodtkorb TH, Knight C, Kamgar F, Teitsson S, Kurt M, Patel MY, Poretta T, Mamtani R, Palmer S (2024) Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective. J Med Econ 27(1):543\u2013\u200953. https:\/\/doi.org\/10.1080\/13696998.2024.2329019","DOI":"10.1080\/13696998.2024.2329019"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05589-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-05589-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05589-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:52:02Z","timestamp":1767966722000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-05589-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5589"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-05589-2","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"assertion":[{"value":"13 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SB, FC and ST are employees of Bristol Myers Squibb, who develop and market immunotherapies for the treatment of MIUC. JC was an employee of VYOO, a contract research organisation which received funding from Bristol Myers Squibb for carrying out this study. CK and LN are employees of RTI Health Solutions, a contract research organisation which received funding from Bristol Myers Squibb for carrying out this study. JB, SN and MR report consultancy fees from Bristol Myers Squibb in the context of this study. In addition, JB reports honoraria from Bristol Myers Squibb, Roche and MSD and grant (institution) from Bristol Myers Squibb. SN reports research funding (institution) from Pfizer and Ipsen and honoraria from Bristol Myers Squibb, Pfizer, Ipsen, Eisa\u00ef and Merck Sharpe and Dohme. MR reports serving on advisory boards for Astellas, Bristol Myers Squibb and Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"202"}}